MX2007000633A - Transgen de la distrofia retinal y metodos de uso del mismo. - Google Patents
Transgen de la distrofia retinal y metodos de uso del mismo.Info
- Publication number
- MX2007000633A MX2007000633A MX2007000633A MX2007000633A MX2007000633A MX 2007000633 A MX2007000633 A MX 2007000633A MX 2007000633 A MX2007000633 A MX 2007000633A MX 2007000633 A MX2007000633 A MX 2007000633A MX 2007000633 A MX2007000633 A MX 2007000633A
- Authority
- MX
- Mexico
- Prior art keywords
- mice
- severe
- transgenic
- dystrophin
- dmd
- Prior art date
Links
- 108010069091 Dystrophin Proteins 0.000 title abstract 4
- 102000001039 Dystrophin Human genes 0.000 title abstract 3
- 108700019146 Transgenes Proteins 0.000 title abstract 2
- 230000002207 retinal effect Effects 0.000 title abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 3
- 208000021642 Muscular disease Diseases 0.000 abstract 2
- 201000009623 Myopathy Diseases 0.000 abstract 2
- 230000005856 abnormality Effects 0.000 abstract 2
- 238000002567 electromyography Methods 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 206010053759 Growth retardation Diseases 0.000 abstract 1
- 206010023509 Kyphosis Diseases 0.000 abstract 1
- 241000699660 Mus musculus Species 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 101100372319 Rattus norvegicus Utrn gene Proteins 0.000 abstract 1
- 208000000875 Spinal Curvatures Diseases 0.000 abstract 1
- 102000011856 Utrophin Human genes 0.000 abstract 1
- 108010075653 Utrophin Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 231100000001 growth retardation Toxicity 0.000 abstract 1
- 230000002962 histologic effect Effects 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 abstract 1
- 238000002601 radiography Methods 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
- 208000016261 weight loss Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La distrofia muscular de Duchenne (DMD) es una enfermedad muscular progresiva que es causada por defectos severos en el gen de la distrofina y da como resultado la muerte del paciente alrededor de la tercera decada. La presente invencion utiliza un raton Doblemente Mutante (DM) como un modelo humano apropiado para la DMD puesto que los ratones son deficientes tanto en la distrofina como en la utrofina (mdxl+, utrn -/-), mueren a los tres meses de edad y padecen de debilidad muscular severa, retardo del crecimiento pronunciado, cifosis, perdida de peso, postura suelta e inmovilidad. La expresion de un transgen de la distrofina retinal humana novedosa Dp260 mostro prevenir la muerte prematura y reducir el fenotipo de distrofia muscular severa a una miopatia clinica moderada. La electromiografia, histologia, radiografia, formacion de imagenes por resonancia magnetica, y estudios de comportamiento concluyeron que los ratones transgenicos DM crecieron normalmente, tuvieron curvatura espinal y movilidad normales, y tuvieron patologia muscular reducida. Los datos EMG e histologicos de ratones DM transgenicos mostraron una disminucion en las anormalidades a los niveles tipicos de la miopatia moderada, mientras que los ratones DM exhibieron las anormalidades severas comunmente observadas en las distrofias humanas. Los ratones DM transgenicos tambien tuvieron niveles de movimiento medibles comparables con aquellos de ratones mdx y controles no tratados.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58870004P | 2004-07-16 | 2004-07-16 | |
| US60825204P | 2004-09-09 | 2004-09-09 | |
| US61302604P | 2004-09-24 | 2004-09-24 | |
| US11/050,911 US20080044393A1 (en) | 2004-07-16 | 2005-02-04 | Retinal dystrophin transgene and methods of use thereof |
| PCT/US2005/025375 WO2006020184A2 (en) | 2004-07-16 | 2005-07-15 | Retinal dystrophin transgene and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007000633A true MX2007000633A (es) | 2008-03-04 |
Family
ID=35907962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007000633A MX2007000633A (es) | 2004-07-16 | 2005-07-15 | Transgen de la distrofia retinal y metodos de uso del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080044393A1 (es) |
| EP (1) | EP1781792A4 (es) |
| JP (1) | JP2008506394A (es) |
| KR (1) | KR20070059058A (es) |
| AU (1) | AU2005274798B2 (es) |
| BR (1) | BRPI0513419A (es) |
| CA (1) | CA2574098A1 (es) |
| IL (1) | IL180734A0 (es) |
| MX (1) | MX2007000633A (es) |
| NZ (1) | NZ553137A (es) |
| WO (1) | WO2006020184A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120142609A1 (en) * | 2009-06-26 | 2012-06-07 | Abdoulaye Sene | Non human animal models for increased retinal vascular permeability |
| WO2016115543A2 (en) * | 2015-01-16 | 2016-07-21 | University Of Washington | Novel micro-dystrophins and related methods of use |
| MA45477A (fr) | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
| EP4282478A3 (en) * | 2016-06-21 | 2024-03-06 | The Curators of the University of Missouri | Modified dystrophin proteins |
| MA52112B1 (fr) * | 2017-03-17 | 2023-08-31 | Res Inst Nationwide Childrens Hospital | Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique du muscle pour traiter la dystrophie musculaire |
| MA47800A (fr) | 2017-03-17 | 2020-01-22 | Univ Newcastle | Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire |
| JP7213238B2 (ja) | 2017-10-18 | 2023-01-26 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するための筋特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5239060A (en) * | 1986-07-25 | 1993-08-24 | The Children's Medical Center Corporation | Muscular dystrophy protein, dystrophin |
| US5541074A (en) * | 1986-07-25 | 1996-07-30 | The Children's Medical Center Corporation | Antibodies to dystrophin and uses therefor |
| CA2165162C (en) * | 1993-06-14 | 2000-05-23 | Hermann Bujard | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US7070771B1 (en) * | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| US6171855B1 (en) * | 1998-05-28 | 2001-01-09 | The Regents Of The University Of Michigan | Vectors |
| AU764686B2 (en) * | 1998-08-28 | 2003-08-28 | Duke University | Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences |
| EP1390490B1 (en) * | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
| EP1420637A4 (en) * | 2001-08-20 | 2005-11-30 | Merck & Co Inc | TRANSGENIC NOSES AS ANIMAL MODELS FOR THE MODULATION OF THE B1 BRADYKININ RECEPTOR PROTEIN |
| US20050208466A1 (en) * | 2002-06-17 | 2005-09-22 | Nagoya Industrial Science Research Institute | Method of selective isolation or visualization of target cells differentiated from embryonic cells or kit for visualization |
-
2005
- 2005-02-04 US US11/050,911 patent/US20080044393A1/en not_active Abandoned
- 2005-07-15 EP EP05775087A patent/EP1781792A4/en not_active Withdrawn
- 2005-07-15 CA CA002574098A patent/CA2574098A1/en not_active Abandoned
- 2005-07-15 AU AU2005274798A patent/AU2005274798B2/en not_active Ceased
- 2005-07-15 KR KR1020077003046A patent/KR20070059058A/ko not_active Application Discontinuation
- 2005-07-15 JP JP2007521712A patent/JP2008506394A/ja active Pending
- 2005-07-15 NZ NZ553137A patent/NZ553137A/en not_active IP Right Cessation
- 2005-07-15 MX MX2007000633A patent/MX2007000633A/es not_active Application Discontinuation
- 2005-07-15 BR BRPI0513419-6A patent/BRPI0513419A/pt not_active IP Right Cessation
- 2005-07-15 WO PCT/US2005/025375 patent/WO2006020184A2/en active Application Filing
-
2007
- 2007-01-16 IL IL180734A patent/IL180734A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080044393A1 (en) | 2008-02-21 |
| IL180734A0 (en) | 2007-06-03 |
| KR20070059058A (ko) | 2007-06-11 |
| BRPI0513419A (pt) | 2008-05-06 |
| JP2008506394A (ja) | 2008-03-06 |
| NZ553137A (en) | 2009-11-27 |
| WO2006020184A3 (en) | 2006-09-14 |
| AU2005274798B2 (en) | 2011-11-17 |
| EP1781792A4 (en) | 2008-01-02 |
| AU2005274798A1 (en) | 2006-02-23 |
| CA2574098A1 (en) | 2006-02-23 |
| WO2006020184A2 (en) | 2006-02-23 |
| EP1781792A2 (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007000633A (es) | Transgen de la distrofia retinal y metodos de uso del mismo. | |
| Massery | Musculoskeletal and neuromuscular interventions: a physical approach to cystic fibrosis. | |
| JP2015536198A (ja) | 頸部固定器 | |
| Nozoe et al. | Phenotypic contrasts of Duchenne Muscular Dystrophy in women: Two case reports | |
| Brown et al. | The responses of leg and trunk muscles to sudden unloading of the hands: implications for balance and spine stability | |
| CN103565437A (zh) | 颈椎屈曲位磁共振检查固定装置 | |
| Dipti et al. | Brown–Vialetto–Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease | |
| CN201211301Y (zh) | 牵引床 | |
| Maruotti et al. | Anesthetic management of a parturient with spinal muscular atrophy type II | |
| CN101091676A (zh) | 一种头托及装有这种头托的颈椎康复电脑工作椅 | |
| WO2023153497A1 (ja) | 姿勢矯正器具 | |
| CN213346628U (zh) | 一种便于使用的神经内科用诊断装置 | |
| Chua et al. | Recurrent sixth nerve palsy associated with a hypoplastic Dorello's canal | |
| CN205198224U (zh) | 一种四维颈椎牵引吊架 | |
| CN207101450U (zh) | 一种可调节护理床起身装置 | |
| Yiu et al. | Infantile-onset myelin protein zero–related demyelinating neuropathy presenting as an upper extremity monoplegia | |
| Choudhury et al. | Neuromuscular scoliosis: clinical presentation, types of deformity, assessment and principles of treatment | |
| Erwin et al. | The effect of posture on respiratory function in patients with obstructive pulmonary emphysema | |
| CN203576503U (zh) | 颈椎屈曲位磁共振检查固定装置 | |
| Hino et al. | Spinal fusion in a patient with Fukuyama congenital muscular dystrophy | |
| Shao | Growth & Development | |
| CN205459480U (zh) | 一种用于小儿脊椎手术的护理床 | |
| CN218129002U (zh) | 基于产科护理用的肢体辅助调节装置 | |
| CN210843669U (zh) | 一种新型矫姿椅 | |
| McDonald et al. | Use of a≥ 5-second threshold in baseline time to stand from supine to predict disease progression in Duchenne muscular dystrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |